Sorcin: a novel potential target in therapies of cancers

References

• Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15:71. doi:10.1186/s12935-015-0221-126180516
   PubMed Web of Science ®Google Scholar
• Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005;14(Suppl 1):35–48. doi:10.1159/000086183
   PubMed Web of Science ®Google Scholar
• Gao Z, Zhang L, Sun Y, et al. Nanotechnology applied to overcome tumor drug resistance. J Control Release. 2012;162(1):45–55. doi:10.1016/j.jconrel.2012.07.02122698943
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ, van der Lelie D, Gang O. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2010;5(4):597–615. doi:10.2217/nnm.10.220528455
   PubMed Web of Science ®Google Scholar
• Kedar U, Phutane P, Shidhaye S, et al. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010;6(6):714–729. doi:10.1016/j.nano.2010.05.00520542144
   PubMed Web of Science ®Google Scholar
• Gothwal A, Khan I, Gupta U. Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm Res. 2016;33(1):18–39. doi:10.1007/s11095-015-1784-126381278
   PubMed Web of Science ®Google Scholar
• Kesharwani SS, Kaur S, Tummala H, et al. Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors. Colloids Surf B. 2019;173:581–590. doi:10.1016/j.colsurfb.2018.10.022
   PubMed Web of Science ®Google Scholar
• Yousefi B, Azimi A, Majidinia M, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARgamma-dependent manner in leukemia cells. Tumour Biol. 2017;39(10):1010428317716501. doi:10.1177/101042831771650128978268
   PubMedGoogle Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162. doi:10.1016/0005-2736(76)90160-7990323
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695–698. doi:10.1073/pnas.86.2.6952563168
   PubMed Web of Science ®Google Scholar
• Kartner N, Evernden-Porelle D, Bradley G, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820–823. doi:10.1038/316820a02412130
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Y, Liang H, et al. P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model. 2011;51(6):1447–1456. doi:10.1021/ci200158321604677
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Yu H, et al. Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today. 2012;17(7–8):343–351. doi:10.1016/j.drudis.2011.11.00322119877
   PubMed Web of Science ®Google Scholar
• de Moraes AC, Maranho CK, Rauber GS, et al. Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy. J Clin Lab Anal. 2013;27(1):62–71. doi:10.1002/jcla.2013.27.issue-123292860
   PubMed Web of Science ®Google Scholar
• Gong Z, Chaaban SA, Meouchy J, et al. Overexpression of sorcin in multidrug-resistant human breast cancer. Oncol Lett. 2014;8(6):2393–2398. doi:10.3892/ol.2014.242625364401
   PubMed Web of Science ®Google Scholar
• Genovese I, Nikolic A, Kentish SJ, et al. Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells. Cell Death Dis. 2017;8(7):e2950. doi:10.1038/cddis.2017.51828726784
   PubMedGoogle Scholar
• Yu X, Mao J, Mahmoud S, et al. Soluble resistance-related calcium-binding protein in cancers. Clin Chim Acta. 2018;486:369–373. doi:10.1016/j.cca.2018.08.03430144438
   PubMed Web of Science ®Google Scholar
• Van der Bliek AM, Meyers MB, Biedler JL, et al. A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain. Embo J. 1986;5(12):3201–3208. doi:10.1002/embj.1986.5.issue-123028774
   PubMed Web of Science ®Google Scholar
• Colotti G, Cao Z-H, Wang B, et al. Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules. 2014;19(9):13976–13989. doi:10.3390/molecules19081121125197934
   PubMed Web of Science ®Google Scholar
• Wang SL, Tam M-F, Ho Y-S, et al. Isolation and molecular cloning of human sorcin a calcium-binding protein in vincristine-resistant HOB1 lymphoma cells. Biochim Biophys Acta. 1995;1260(3):285–293. doi:10.1016/0167-4781(94)00206-I7873602
   PubMedGoogle Scholar
• Shabnam B, Padmavathi G,  Banik K, et al. Sorcin a potential molecular target for cancer therapy. Transl Oncol. 2018; 11(6):1379–1389. doi:10.1016/j.tranon.2017.10.004 Reprinted from Transl Oncol, Volume 11, Issue 6, Shabnam, B., et al., Sorcin a Potential Molecular Target for Cancer Therapy, Pages 1379-1389, 2018, with permission from Elsevier. No modifying material in this review. The link of formal publication: 10.1016/j.tranon.2018.08.015. Under a Creative Commons user license: https://creativecommons.org/licenses/by-nc-nd/4.0/.30216763
   PubMed Web of Science ®Google Scholar
• Lalioti VS, Ilari A, O’Connell DJ, et al. Sorcin links calcium signaling to vesicle trafficking, regulates Polo-like kinase 1 and is necessary for mitosis. PLoS One. 2014;9(1):e85438.24427308
   PubMed Web of Science ®Google Scholar
• Suarez J, Belke DD, Gloss B, et al. In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2004;286(1):H68–75. doi:10.1152/ajpheart.00245.200312958030
   PubMed Web of Science ®Google Scholar
• Seidler T, Miller SLW, Loughrey CM, et al. Effects of adenovirus-mediated sorcin overexpression on excitation-contraction coupling in isolated rabbit cardiomyocytes. Circ Res. 2003;93(2):132–139. doi:10.1161/01.RES.0000081596.90205.E212805242
   PubMed Web of Science ®Google Scholar
• Meyers MB, Fischer A, Sun Y-J, et al. Sorcin regulates excitation-contraction coupling in the heart. J Biol Chem. 2003;278(31):28865–28871. doi:10.1074/jbc.M30200920012754254
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Hisamatsu Y, Ohkusa T, et al. Sorcin interacts with sarcoplasmic reticulum Ca(2+)-ATPase and modulates excitation-contraction coupling in the heart. Basic Res Cardiol. 2005;100(3):250–262. doi:10.1007/s00395-005-0518-715754088
   PubMed Web of Science ®Google Scholar
• Ilari A, Johnson KA, Nastopoulos V, et al. The crystal structure of the sorcin calcium binding domain provides a model of Ca2+-dependent processes in the full-length protein. J Mol Biol. 2002;317(3):p. 447–58. doi:10.1006/jmbi.2002.5417
   PubMed Web of Science ®Google Scholar
• Mella M, Colotti G, Zamparelli C, et al. Information transfer in the penta-EF-hand protein sorcin does not operate via the canonical structural/functional pairing. A study with site-specific mutants. J Biol Chem. 2003;278(27):24921–24928. doi:10.1074/jbc.M21327620012711611
   PubMed Web of Science ®Google Scholar
• Chen X, Weber C, Farrell ET, et al. Sorcin ablation plus β-adrenergic stimulation generate an arrhythmogenic substrate in mouse ventricular myocytes. J Mol Cell Cardiol. 2018;114:199–210. doi:10.1016/j.yjmcc.2017.11.01729174767
   PubMed Web of Science ®Google Scholar
• Marmugi A, Richardson CC, Ravishankar A, et al. Sorcin links pancreatic beta-cell lipotoxicity to ER Ca2+ stores. Diabetes. 2016;65(4):1009–1021. doi:10.2337/db15-105826822088
   PubMed Web of Science ®Google Scholar
• Groebe K, Cen J, Schvartz D, et al. Palmitate-induced insulin hypersecretion and later secretory decline associated with changes in protein expression patterns in human pancreatic islets. J Proteome Res. 2018;17(11):3824–3836. doi:10.1021/acs.jproteome.8b0023930183308
   PubMed Web of Science ®Google Scholar
• Li X, Yildirim-Aksoy M, Klesius PH, et al. Engagement of soluble resistance-related calcium binding protein (sorcin) with foot-and-mouth disease virus (FMDV) VP1 inhibits type I interferon response in cells. Vet Microbiol. 2013;166(1–2):35–46. doi:10.1016/j.vetmic.2013.07.02523764275
   PubMed Web of Science ®Google Scholar
• Tran GVQ, Luong TTD, Park E-M, et al. Nonstructural 5A protein of hepatitis C virus regulates soluble resistance-related calcium-binding protein activity for viral propagation. J Virol. 2016;90(6):2794–2805. doi:10.1128/JVI.02493-15
   Web of Science ®Google Scholar
• Lim HJ, Kocarnik JM, Bush WS, et al. Alteration in endometrial proteins during early- and mid-secretory phases of the cycle in women with unexplained infertility. PLoS One. 2014;9(11). doi:10.1371/journal.pone.0089791
   Web of Science ®Google Scholar
• Gupta K, Sirohi VK, Kumari S, et al. Sorcin is involved during embryo implantation via activating VEGF/PI3K/Akt pathway in mice. J Mol Endocrinol. 2018;60(2):119–132. doi:10.1530/JME-17-015329273681
   PubMed Web of Science ®Google Scholar
• Xie H, Chang M, Hu X, et al. Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells. Neurol Sci. 2011;32(2):221–228. doi:10.1007/s10072-010-0340-320563739
   PubMed Web of Science ®Google Scholar
• Kim SI, Li H-M, Lee YZ, et al. Sequestration of sorcin by aberrant forms of tau results in the defective calcium homeostasis. Korean J Physiol Pharmacol. 2016;20(4):387–397. doi:10.4196/kjpp.2016.20.2.17727382355
   PubMed Web of Science ®Google Scholar
• Krakhmal NV, Zavyalova MV, Denisov EV, et al. Cancer invasion: patterns and mechanisms. Acta Naturae. 2015;7(2):17–28.26085941
   PubMed Web of Science ®Google Scholar
• Huan Tuo FS, She S, Yang M, et al. Sorcin induces gastric cancer cell migration and invasion contributing to STAT3 activation. Oncotarget 2017;8(61):104258–104271.
   Google Scholar
• Deng L, Li M, Zhang G, et al. Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol. 2010;27(4):1102–1108. doi:10.1007/s12032-009-9208-x19885748
   PubMed Web of Science ®Google Scholar
• Tong W, Sun D, Wang Q, et al. Sorcin enhances metastasis and promotes epithelial-to-mesenchymal transition of colorectal cancer. Cell Biochem Biophys. 2015;72(2):453–459. doi:10.1007/s12013-014-0486-325567655
   PubMed Web of Science ®Google Scholar
• Landriscina M, Laudiero G, Maddalena F, et al. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res. 2010;70(16):6577–6586. doi:10.1158/0008-5472.CAN-10-125620647321
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58. doi:10.1038/nrc70611902585
   PubMed Web of Science ®Google Scholar
• Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J. 2007;13(5):271–275. doi:10.1097/PPO.0b013e318156da4e17921723
   PubMed Web of Science ®Google Scholar
• Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012;31(1–2):277–283. doi:10.1007/s10555-011-9344-622215472
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J, Navarro M, et al. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–4751. doi:10.1038/onc.2010.37820531305
   PubMed Web of Science ®Google Scholar
• Hu Y, Li S, Yang M, et al. Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat. 2014;143(2):287–299. doi:10.1007/s10549-013-2809-224337682
   PubMed Web of Science ®Google Scholar
• Patton AM, Kassis J, Doong H, et al. Calcium as a molecular target in angiogenesis. Curr Pharm Des. 2003;9(7):543–551. doi:10.2174/138161203339155912570802
   PubMed Web of Science ®Google Scholar
• Lodola F, Laforenza U, Bonetti E, et al. Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One. 2012;7(9):e42541.23049731
   PubMed Web of Science ®Google Scholar
• Qu Y, Li M, Zhang G, et al. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Med Oncol. 2010;27(4):p. 1303–8. doi:10.1007/s12032-009-9208-x
   PubMed Web of Science ®Google Scholar
• Gao Y, LI W, LIU X, et al. Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells. Mol Med Rep. 2015;11(3):2118–2124. doi:10.3892/mmr.2014.293625394367
   PubMed Web of Science ®Google Scholar
• Liu X, Chen L, Feng B, et al. Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma. Anat Rec (Hoboken). 2014;297(2):215–221. doi:10.1002/ar.v297.224376145
   PubMedGoogle Scholar
• Dabaghi M, Rahgozar S, Moshtaghian J, et al. Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp. Genet Test Mol Biomarkers. 2016;20(9):516–521. doi:10.1089/gtmb.2016.003127382961
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu Y, Tan Y, et al. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res. 2006;30(4):469–476. doi:10.1016/j.leukres.2005.08.02416213583
   PubMed Web of Science ®Google Scholar
• Tan Y, Li G, Zhao C, et al. Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res. 2003;27(2):125–131. doi:10.1016/S0145-2126(02)00083-812526918
   PubMed Web of Science ®Google Scholar
• Qinghong S, Shen G, Lina S, et al. Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous leukemia cell lines. Proteome Sci. 2015;13(1):1. doi:10.1186/s12953-014-0057-y25628518
   PubMedGoogle Scholar
• Li GY, Wang GX, Yang XM, et al. Relationship of sorcin gene expression and multidrug resistance in multiple myeloma patients. Shandong Med J. 2002;(06):1–4.
   Google Scholar
• Xu P, Jiang YF, Wang JH. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines. Int J Clin Exp Pathol. 2015;8(3):2300–2310.26045737
   PubMed Web of Science ®Google Scholar
• Till BG. Maintenance therapy in diffuse large B cell lymphoma and mantle cell lymphoma. Curr Treat Options Oncol. 2018;19(9):45. doi:10.1007/s11864-018-0561-x30032463
   PubMed Web of Science ®Google Scholar
• Maxwell SA, Cherry EM, Bayless KJ, et al. Akt, 14-3-3zeta, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(5):849–864. doi:10.3109/10428194.2010.53518221323512
   PubMed Web of Science ®Google Scholar
• Lee WP. Purification, cDNA cloning, and expression of human sorcin in vincristine-resistant HOB1 lymphoma cell lines. Arch Biochem Biophys. 1996;325(2):217–226. doi:10.1006/abbi.1996.00278561500
   PubMed Web of Science ®Google Scholar
• Kawakami M, Nakamura T, Okamura N, et al. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. Biol Pharm Bull. 2007;30(6):1065–1073. doi:10.1248/bpb.30.106517541155
   PubMed Web of Science ®Google Scholar
• Demidova NS, Ilyinskaya GV, Shiryaeva OA, et al. Decreased sensitivity of multidrug-resistant tumor cells to cisplatin is correlated with sorcin gene co-amplification. Neoplasma. 1995;42(4):195–201.7659186
   PubMed Web of Science ®Google Scholar
• Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(2):93–105. doi:10.2174/187446721080102009319079736
   PubMedGoogle Scholar
• Robert J, Larsen AK. Drug resistance to topoisomerase II inhibitors. Biochimie. 1998;80(3):247–254. doi:10.1016/S0300-9084(98)80007-29615864
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398. doi:10.1146/annurev.pharmtox.39.1.36110331089
   PubMed Web of Science ®Google Scholar
• Yamagishi N, Nakao R, Kondo R, et al. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. Biochem Biophys Res Commun. 2014;448(4):430–436. doi:10.1016/j.bbrc.2014.04.12524796664
   PubMed Web of Science ®Google Scholar
• Van der Bliek AM, Baas F, Van der Velde-Koerts T, et al. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res. 1988;48(21):5927–5932.2901906
   PubMed Web of Science ®Google Scholar
• Xue C, Wang C, Sun Y, et al. Targeting P-glycoprotein function, p53 and energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Oncotarget. 2017;8(5):8622–8632.28052008
   PubMedGoogle Scholar
• Xue C, Wang C, Liu Q, et al. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Tumour Biol. 2016;37(7):8587–8597. doi:10.1007/s13277-015-4478-826733176
   PubMedGoogle Scholar
• Chen T, Jane EP, Pollack IF, et al. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther. 2015;16(1):106–114. doi:10.4161/15384047.2014.98754825482933
   PubMed Web of Science ®Google Scholar
• Hu Y, Cheng X, Li S, et al. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol. 2013;72(4):789–798. doi:10.1007/s00280-013-2254-224013575
   PubMed Web of Science ®Google Scholar
• Beyer-Sehlmeyer G, Hiddemann W, Wörmann B, et al. Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin. Eur J Cancer. 1999;35(12):1735–1742. doi:10.1016/S0959-8049(99)00202-610674022
   PubMed Web of Science ®Google Scholar
• Padar S, Kuroda Y, Sawa S, et al. Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol. 2004;142(2):305–316. doi:10.1038/sj.bjp.070557515066902
   PubMed Web of Science ®Google Scholar
• Wang T, Pei FY, Wang Q, et al. Relationship of sorcin over-expression to multidrug resistance of human lung cancer cell line NCI-H446. J Dalian Med Uni. 2013;35(05):420–423+433.
   Google Scholar
• Chuthapisith S, Layfield R, Kerr ID, et al. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol. 2007;30(6):1545–1551.17487377
   PubMed Web of Science ®Google Scholar
• He Q, Tang B, Liu Y, et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep. 2011;25(1):237–243. doi:10.3892/or.2011.117521109982
   PubMed Web of Science ®Google Scholar
• Li J, Kang Z-J, Huang S-Y, et al. [Influence of tetrandrine on SORCIN gene expression in K562/A02 cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16(1):65–69.18315902
   PubMedGoogle Scholar
• Li GY, Zhang L, Liu J-Z, et al. Marine drug Haishengsu increases chemosensitivity to conventional chemotherapy and improves quality of life in patients with acute leukemia. Biomed Pharmacother. 2016;81:160–165. doi:10.1016/j.biopha.2016.04.00527261590
   PubMed Web of Science ®Google Scholar
• Li GY, Liu JZ, Zhang B, et al. Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice. Adv Med Sci. 2013;58(1):112–117. doi:10.2478/v10039-012-0069-823729583
   PubMed Web of Science ®Google Scholar
• Tan Y, Qi J, Liu WJ, et al. Preliminary studies on the mechanisms of a new anti-tumor agent PH Ⅱ-7 with special preference to multidrug resistant tumor cells. Acta Academiae Medicinae Sinicae. 2002;(02):134–139.12905789
   PubMedGoogle Scholar
• Xing CL, Li GY, Wang J, et al. Effect of cyclosporin A on sorcin gene expression and clinical effect in multiple myeloma patients. Shandong Med J. 2007;(11):10–11.
   Google Scholar
• Sun Y, Liu W, Wang C, et al. Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: a new strategy of inhibiting P-glycoprotein. J Cell Physiol. 2018.
   Web of Science ®Google Scholar